SRR23303774
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.410
- G2M_CHECKPOINT+0.370
- KRAS_SIGNALING_DN+0.280
- SPERMATOGENESIS+0.250
- MITOTIC_SPINDLE+0.070
- PANCREAS_BETA_CELLS+0.050
- HEDGEHOG_SIGNALING+0.040
- ESTROGEN_RESPONSE_LATE+0.020
- APICAL_SURFACE-0.020
- BILE_ACID_METABOLISM-0.020
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.470
- INTERFERON_ALPHA_RESPONSE-0.470
- OXIDATIVE_PHOSPHORYLATION-0.440
- INTERFERON_GAMMA_RESPONSE-0.410
- ADIPOGENESIS-0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.350
- TGF_BETA_SIGNALING-0.350
- COMPLEMENT-0.340
- PROTEIN_SECRETION-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013518 | — | cohortSQ1 | 0.905 |
| 2 | SRR6013541 | — | cohortSQ1 | 0.899 |
| 3 | BS_44A3ES23 | medulloblastoma | — | 0.891 |
| 4 | MNG459 | — | — | 0.890 |
| 5 | BS_JVW2JJ39 | high-grade glioma | — | 0.883 |
| 6 | BS_JT82QGXF | medulloblastoma | — | 0.882 |
| 7 | BS_4E1G7E3G | ATRT | — | 0.880 |
| 8 | SRR22247242 | — | cohortSC | 0.876 |
| 9 | MNG1288 | — | — | 0.876 |
| 10 | BS_VAAHBH60 | EPN | Supratentorial EPN | 0.874 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.280 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.070 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.050 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.040 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.020 | Idelalisib | — uncovered |